QuidelOrtho QDEL

Mr. Blaser has served as our President and CEO since May 6, 2024 and a director since May 15, 2024. Prior to that, Mr. Blaser most recently served as Executive Vice President, Diagnostic Products of Abbott Laboratories, a global medical device company, from 2012 to June 2019, where he oversaw the company's global diagnostics organization, including its core laboratory, point of care, rapid diagnostics and molecular diagnostics businesses. Prior to that role, Mr. Blaser served in various strategic, operational and diagnostic roles at Abbott Laboratories, since joining the company in 2004. Previously, he served in various leadership positions in operations, finance and engineering at the Ortho Clinical Diagnostics division of Johnson & Johnson, Eastman Kodak and General Motors. Mr. Blaser served on the board of directors of Quanterix Corp., a life sciences company, from 2023 to 2024. He also previously served on the board of directors of Meridian Bioscience Inc. and as senior advisor to McKinsey & Company. He currently serves as the Advisory Council Chair of the University of Dayton School of Engineering and a director of Advanced Medical Technology Association. Mr. Blaser received his M.B.A. with a Finance concentration from the Rochester Institute of Technology and his B.Sc. in Mechanical Engineering Technology from the University of Dayton. Prior Public Company Directorships Within the Past 5 Years: Quanterix Corp. until 2024.

Mr. Philip D. McLellan became our Chief Operations Officer (COO) in November 2024. From November 2020 to November 2024, Mr. McLellan served as our SVP of Operations. Prior to joining us, Mr. McLellan led the division operations teams for several different life sciences divisions at Thermo Fisher Scientific for 11 years, including the Laboratory Consumables, Genetic Analysis, and Bioproduction businesses. Prior to that, he had several global automotive manufacturing roles with Toyota Motor Manufacturing for 13 years. Mr. McLellan received his B.S. in Mechanical Engineering from Georgia Institute of Technology.

Mr. Jonathan Philip Siegrist became our EVP of R&D and Chief Technology Officer (CTO) in October 2024. Prior to joining us, Dr. Siegrist served in various senior R&D positions during his tenure at Cepheid, a molecular diagnostics company owned by the Danaher corporation, since 2011, including as Chief Technology Officer and Head of Assay R&D from December 2023 to October 2024, as Chief Technology Officer from 2021 to 2023, and as Vice President, Technology & Innovation from 2018 to 2021. In these roles, he was responsible for leading R&D teams to pursue new technologies, assays and systems. Dr. Siegrist received his Ph.D. and Master of Science in Biomedical Engineering from the University of California, Irvine and his B.S. in Electrical Engineering from the University of California, Los Angeles.

Dr. Kenneth F. Buechler, PhD has served as the Chair of the Board since December 2022, and from August 2015 to May 2022. He previously served as the Lead Independent Director from May 2022 to December 2022. Dr. Buechler co-founded Biosite Inc. and held various roles there from 1988 until its acquisition by Alere Inc. in 2007, including serving as a director, President and Chief Scientific Officer, Senior Vice President, Research and Development, and Vice President, Research and Director of Chemistry. Prior to co-founding Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Inc. Dr. Buechler currently serves as a director of TriVirum, Inc. He previously served as chair of the board of directors of Sequenom Inc., a life sciences company, until its acquisition in September 2016, on the board of directors of Astute Medical Inc., a company that develops biomarkers for acute medical conditions, until its acquisition in April 2018, and on the board of directors of Edico Genome Inc., a DNA sequencing technology company, until its acquisition in May 2018. Dr. Buechler received his Ph.D. in Biochemistry and his bachelor's degree in Chemistry from Indiana University.

Dr. Kenneth J. Widder, M.D. has more than 30 years of experience working with biomedical companies. Dr. Widder previously served as the Executive Chair of OrphoMed Inc., a clinical-stage biopharmaceutical company, from 2017 to 2022, and was a founder, chair and Chief Executive Officer of Sydnexis, Inc., a private company developing low dose atropine for the treatment of myopia progression in children, from 2017 to 2022. Dr. Widder was a General Partner with LVP Life Science Ventures, a venture capital company for biotechnology and medical device start-ups, from 2007 to 2016. Dr. Widder holds an M.D. from Northwestern University and trained in pathology at Duke University. Other Current Public Company Directorships: Personalis, Inc. - Audit Committee and Nominating and Corporate Governance Committee. Prior Public Company Directorships Within the Past 5 Years: Evoke Pharma, Inc. until December 2025.

Mr. Edward L. Michael is the Managing Partner of LionBird Ventures, a venture capital firm he co-founded in 2012, which focuses on investing in digital health and business services companies. For nearly 27 years, Mr. Michael held a variety of roles at Abbott Laboratories, including most recently as Executive Vice President, Diagnostic Products and previously in legal, commercial and operational roles in various Abbott divisions. Mr. Michael currently serves on the boards of directors of certain private LionBird portfolio companies. Mr. Michael received his B.A. from Indiana University and a J.D. from Indiana University School of Law.

Ms. Ann D. Rhoads most recently served as Chief Financial Officer of Forty Seven, Inc., a formerly publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was the Executive Vice President and Chief Financial Officer of Zogenix, Inc., a formerly publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was the Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Business School. Other Current Public Company Directorships: Globus Medical Inc. - Audit Committee (chair) and Nominating and Corporate Governance Committee. Prior Public Company Directorships Within the Past 5 Years: iTeos Therapeutics until August 2025 - Audit Committee (chair), Compensation Committee and Nominating and Corporate Governance Committee, Repare Therapeutics until January 2026 - Audit Committee (chair) and Nominating and Corporate Governance Committee.

Mr. John R. Chiminski most recently served as the Executive Chair of Catalent, Inc., a global contract development and manufacturing organization, from July 2022 to June 2023, and previously served as its President and Chief Executive Officer from March 2009 to July 2022. He joined Catalent after more than 20 years of experience at GE Healthcare in engineering, operations, and senior leadership roles. From 2007 to 2009, Mr. Chiminski was President and Chief Executive Officer of GE Medical Diagnostics. From 2005 to 2007, he served as Vice President and General Manager of GE Healthcare's Global Magnetic Resonance Business, and from 2001 to 2005, as Vice President and General Manager of Global Healthcare Services. Earlier at GE, he held various cross-functional leadership positions in both manufacturing and engineering. Mr. Chiminski currently serves as a director of Radiology Partners, Inc., a company that provides technology-enabled radiology services. Mr. Chiminski holds a B.S. from Michigan State University and an M.S. from Purdue University, both in electrical engineering, as well as a Master's degree in Management from the Kellogg School of Management at Northwestern University.

Dr. Mary Lake Polan, M.D.,PhD served as an Adjunct Professor in the Department of Obstetrics and Gynecology at Columbia University School of Medicine from 2007 to 2014. She rejoined the Department of Obstetrics and Gynecology at Yale University School of Medicine as a Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences in 2015. Dr. Polan previously served as a Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine from 1990 to 2005, and before that served on the faculty at Yale University. Dr. Polan received a B.A. degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her M.P.H. from the University of California, Berkeley. Dr. Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr. Polan also serves as a director at the following private companies: NX Prenatal Inc., Or-Genix Therapeutics, Inc., Residents Diagnostics, Inc., MiraDx, Inc. and FABBiopharma, Inc. Prior Public Company Directorships Within the Past 5 Years: ChemBio Diagnostics until 2021.

Mr. Scott Huennekens most recently served as Interim President and Chief Executive Officer of Hyperfine, Inc., a medical technology company, from July 2022 to October 2022. Prior to this role, he served as the President, Chief Executive Officer and chair of the board of directors of Verb Surgical, Inc. from August 2015 to January 2019. Prior to joining Verb Surgical, Mr. Huennekens was President, Chief Executive Officer and a board member of Volcano Corporation from March 2002 to February 2015. Mr. Huennekens currently serves as chair of the board of directors of Envista Holdings Corporation and as a director of NeuroPace Inc. He was previously on the boards of directors of Acutus Medical, Inc., NuVasive, Inc., Reva Medical, Inc., ViewRay, Inc., EndoChoice Holdings, Bellerophon Therapeutics Inc. and Hyperfine, Inc. Mr. Huennekens holds a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard Business School. Other Current Public Company Directorships: Envista Holdings Corporation - Audit Committee and Nominating and Governance Committee; NeuroPace Inc. - Audit Committee. Prior Public Company Directorships Within the Past 5 Years: Acutus Medical, Inc. until January 2024; Hyperfine, Inc. until May 2025.

Ms. Evelyn S. Dilsaver previously served as President and Chief Executive Officer of Charles Schwab Investment Management, the mutual fund arm of The Charles Schwab Corporation, from 2004 to 2007. Prior to that, Ms. Dilsaver served in various leadership roles at The Charles Schwab Corporation for more than 16 years beginning in 1991, including as Executive Vice President and Senior Vice President, Asset Management Products and Services of Charles Schwab Investment Management. Ms. Dilsaver also serves as a director of Bailard Private Real Estate Fund, a private company, and as an advisory board member at Protiviti Inc. Ms. Dilsaver received her B.A. in Accounting from California State University-Hayward, School of Business and Economics and participated in the Stanford Graduate School of Business, Senior Executive Program. Other Current Public Company Directorships: Tempur Sealy International Inc. - Audit Committee (chair) and Nominating and Corporate Governance Committee; Health Equity, Inc. - Nominating and Corporate Governance Committee (chair); PACS Group - Nominating and Corporate Governance Committee (chair), Audit Committee and Compensation Committee; Prior Public Company Directorships Within the Past 5 Years: Ortho until May 2022 - Audit Committee (chair);

Mr. Joseph D. Wilkins, Jr serves as senior advisor for THEO Transformation Advisory, an advisory group, and has served in this position since October 2022. Previously, Mr. Wilkins served as Senior Vice President and Chief Transformation and Innovation Officer for Atlantic Health System, an integrated healthcare delivery system, from October 2016 to October 2018. Mr. Wilkins previously led commercial operations teams at Quest Diagnostics. He also held various executive leadership roles at Danaher-Beckman Coulter for approximately 28 years. Mr. Wilkins serves on the board of directors of Providence Health and Services, one of the nation's largest healthcare systems, and the board of TGR Foundation, founded by Tiger Woods. Mr. Wilkins earned a B.A. and an M.B.A. in healthcare finance from Argosy University, is board-certified in healthcare management and serves as a Fellow of the American College of Healthcare Executives. Prior Public Company Directorships Within the Past 5 Years: Catalent, Inc. until 2023; PhenomeX Inc. until 2023.

The Board of Directors of QuidelOrtho Corporation has appointed Micah Young to serve as the Company's Chief Financial Officer and principal financial officer, effective as of July 6, 2026. Mr. Young most recently served as Executive Vice President and Chief Financial Officer of Masimo Corporation (formerly, Nasdaq: MASI), a global medical technology company, from October 2017 until Masimo's acquisition by Danaher Corporation in June 2026. In this role, Mr. Young was responsible for finance and accounting functions, as well as investor relations, information technology and corporate development. From 2009 to 2017, Mr. Young served in various finance roles at NuVasive, Inc. (formerly, Nasdaq: NUVA), a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders, including most recently as Vice President, Finance. From 2002 to 2009, Mr. Young held various accounting and finance positions with Zimmer Holdings, Inc., a company focused on the design, development, manufacture and marketing of orthopedic reconstructive, spinal and trauma devices, dental implants and related surgical products. Prior to his time at Zimmer Holdings, Inc., Mr. Young was an auditor at Deloitte & Touche LLP from 2000 to 2002. He holds a B.S. in Accounting and Criminal Justice from Indiana Wesleyan University and is a Certified Public Accountant (inactive).

Mr. Ronald Lee Bowman became our Chief Human Resources Officer in August 2024. Prior to joining us, Mr. Bowman served as Senior Vice President and Chief People Officer of RadNet, a diagnostic imaging services company, from May 2022 to November 2023, and as Senior Vice President, Global Human Resources of Edwards Lifesciences, a healthcare technology company, from 2019 to 2022, where he oversaw global human resources operations, organizational effectiveness and innovation. Mr. Bowman received his M.B.A. from San Diego State University and his B.S. in Psychology from Towson University.

Mr. Bryan Michael Hanson became our Executive Vice President (EVP), Global Portfolio Management and Marketing in February 2026. From November 2024 to February 2026, Mr. Hanson served as our Senior Vice President (SVP), Clinical Labs and Transfusion Medicine, and from October 2023 to November 2024, he served as our President of North America Commercial Operations. Prior to joining us, Mr. Hanson served in various sales, marketing and operational roles with Ortho from June 2014 to May 2022 and at Johnson & Johnson from January 2008 to June 2014. Mr. Hanson received his B.A. in Business Administration from University of North Dakota. He also holds a certificate in strategic marketing management from The Wharton School of the University of Pennsylvania.

Nathaniel Nate Sisitsky was appointed as Chief Legal Officer effective March 23, 2026. Nathaniel Sisitsky leads the company's global legal, compliance and corporate governance functions. He advises the executive leadership team and our Board of Directors on corporate governance, regulatory matters, strategic transactions and risk management, supporting the company's long-term growth and operational priorities. Prior to joining QuidelOrtho, Mr. Sisitsky most recently served as Chief Legal Officer and Corporate Secretary at STAAR Surgical Company, where he led global legal and compliance functions and supported key strategic initiatives. Prior to that, he served as Senior Vice President, General Counsel and Corporate Secretary at NuVasive, Inc., where he oversaw global legal operations and played a key role in the company's $3.1 billion merger with Globus Medical, Inc. He also held senior legal leadership roles at CareFusion Corporation and American Tower Corporation and began his career at Wilmer Cutler Pickering Hale and Dorr LLP. Mr. Sisitsky holds a Juris Doctor degree from New York University School of Law and a Bachelor of Arts in Political Science and Economics from Emory University.